Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Towards Optimizing Value-Based Systemic Therapy in Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis Using Decision Analytic Modeling of First-Line Systemic Therapy

EF 2018-19

Résumé
Given a better understanding of how kidney cancers behave, there have been several new drugs developed over the last decade that are effective against this disease. While this is exciting for patients, it creates a decision-making problem for clinicians to identify the most effective treatment for individuals. Clinical trials have typically provided the necessary data to inform these decisions. Unfortunately, given the significant cost of clinical trials and the growing number of new drug treatments, it is impractical to conduct clinical trials to test all potential comparator treatments with one another. As such there is great need to develop new methods to systematically compare all drugs for kidney cancer to help decide the most effective treatment. Further, although it would be ideal to fund all new drugs, given the significant costs associated with these new treatments, our publicly funded health care system is unable to sustain this. Therefore, to inform health care policy makers on the most effective treatment for public funding, we require a method to compare both the cost and effectiveness of treatments, particularly when there is an absence of clinical trial data. The current research project aims to evaluate and compare the cost and effectiveness of all currently available first-line drug treatments for kidney cancer. This will be done through the use of decision-analytic modeling. This technique allows for the simulation of “mock” clinical trials to compare drug treatments that have not been compared directly, under different conditions. Overall, we anticipate the results of this study will provide the necessary information to help clinicians and policy-makers to choose the best first-line drug treatments for our patients with kidney cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406371
Name
Parmar Ambika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Towards Optimizing Value-Based Systemic Therapy in Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis Using Decision Analytic Modeling of First-Line Systemic Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cost-Effectiveness; Decision-Analysis; Health Services Research; Health Technology Assessment; Immunotherapy; Oncology; Renal Cell Carcinoma; Targeted Therapy
Abstract
Given a better understanding of how kidney cancers behave, there have been several new drugs developed over the last decade that are effective against this disease. While this is exciting for patients, it creates a decision-making problem for clinicians to identify the most effective treatment for individuals. Clinical trials have typically provided the necessary data to inform these decisions. Unfortunately, given the significant cost of clinical trials and the growing number of new drug treatments, it is impractical to conduct clinical trials to test all potential comparator treatments with one another. As such there is great need to develop new methods to systematically compare all drugs for kidney cancer to help decide the most effective treatment. Further, although it would be ideal to fund all new drugs, given the significant costs associated with these new treatments, our publicly funded health care system is unable to sustain this. Therefore, to inform health care policy makers on the most effective treatment for public funding, we require a method to compare both the cost and effectiveness of treatments, particularly when there is an absence of clinical trial data. The current research project aims to evaluate and compare the cost and effectiveness of all currently available first-line drug treatments for kidney cancer. This will be done through the use of decision-analytic modeling. This technique allows for the simulation of “mock” clinical trials to compare drug treatments that have not been compared directly, under different conditions. Overall, we anticipate the results of this study will provide the necessary information to help clinicians and policy-makers to choose the best first-line drug treatments for our patients with kidney cancer.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Parmar, Ambika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~